The National Health Insurance Civilian Surveillance Alliance yesterday questioned the legitimacy of a certification for pharmaceutical manufacturers after a majority of the manufacturers that were required by the Food and Drug Administration (FDA) to re-file bioequivalence testing (BE) reports for changes made to their products were awarded PIC/S GMP or GMP certification.
BE testing is conducted to ensure that a generic drug delivers the same therapeutic effect as a reference brand-name pharmaceutical.
In response, the agency said that the changes to the drugs were “legitimate” and have no negative impact on drug safety.
Photo: Wei Yi-chia, Taipei Times
At the end of August, the health insurance watchdog held a press conference to report that as many as 3,841 drug products failed to comply with pharmaceutical regulations after making changes to package inserts, packaging and the excipients used in drugs without seeking re-approval by the regulator.
In response, the agency promised to hold risk assessment meetings to evaluate the drugs that had been altered.
This month, the agency announced that 33 out of 3,841 generic drug products would need to be tested for their bioequivalence with brand-name medicines, with 21 more to be examined.
The group found that 10 of the 11 drug manufacturers that produce the 33 drugs are PIC/S GMP (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, or the guide to Good Manufacturing Practice for medicinal products) or GMP certified.
“The government has required all pharmaceutical manufacturers to be PIC/S-certified by the end of next year, after which those without will not be permitted to make or sell drugs in Taiwan,” alliance spokeswoman Eva Teng (滕西華) said.
“However, the 10 manufacturers account for 15.8 percent of the 57 PIC/S GMP-certified manufacturers in the country. This makes us concerned that the certification does not guarantee drug quality,” Teng added.
The lack of BE testing reports for drugs that have been altered is a major problem, the group said.
“Changing the excipient, the diluent or the vehicle of a drug could decrease its therapeutic effect,” alliance convener Huang Sue-ying (黃淑英) said, adding that the agency should have ordered that the 33 drug products be pulled off shelves immediately after the announcement this month.
“The agency asked doctors to look for substitutes as soon as possible, and said that the drugs were without health risks,” she said.
FDA official Chi Jo-feng (祁若鳳) said that the PIC/S GMP certificate would not be revoked unless the violations are “grave,” such as producing counterfeit drugs, adding that the drugs were not withdrawn from the market immediately because some patients need time to switch to a new drug.
The agency updated the list in a statement yesterday, announcing the final result of the assessment for the need of BE testing on a total of 54 drugs (including the 33 announced earlier), which said that only nine of the 54 would need to redo BE testing.
One of the 33 drugs required to be tested this month was made exempt because the manufacturer had subsequently handed in relevant documents, while several others decided to revert to the original formula or simply give up the permit for the drug and had their products pulled off shelves, an FDA official said.
‘DENIAL DEFENSE’: The US would increase its military presence with uncrewed ships, and submarines, while boosting defense in the Indo-Pacific, a Pete Hegseth memo said The US is reorienting its military strategy to focus primarily on deterring a potential Chinese invasion of Taiwan, a memo signed by US Secretary of Defense Pete Hegseth showed. The memo also called on Taiwan to increase its defense spending. The document, known as the “Interim National Defense Strategic Guidance,” was distributed this month and detailed the national defense plans of US President Donald Trump’s administration, an article in the Washington Post said on Saturday. It outlines how the US can prepare for a potential war with China and defend itself from threats in the “near abroad,” including Greenland and the Panama
The High Prosecutors’ Office yesterday withdrew an appeal against the acquittal of a former bank manager 22 years after his death, marking Taiwan’s first instance of prosecutors rendering posthumous justice to a wrongfully convicted defendant. Chu Ching-en (諸慶恩) — formerly a manager at the Taipei branch of BNP Paribas — was in 1999 accused by Weng Mao-chung (翁茂鍾), then-president of Chia Her Industrial Co, of forging a request for a fixed deposit of US$10 million by I-Hwa Industrial Co, a subsidiary of Chia Her, which was used as collateral. Chu was ruled not guilty in the first trial, but was found guilty
A wild live dugong was found in Taiwan for the first time in 88 years, after it was accidentally caught by a fisher’s net on Tuesday in Yilan County’s Fenniaolin (粉鳥林). This is the first sighting of the species in Taiwan since 1937, having already been considered “extinct” in the country and considered as “vulnerable” by the International Union for Conservation of Nature. A fisher surnamed Chen (陳) went to Fenniaolin to collect the fish in his netting, but instead caught a 3m long, 500kg dugong. The fisher released the animal back into the wild, not realizing it was an endangered species at
DEADLOCK: As the commission is unable to forum a quorum to review license renewal applications, the channel operators are not at fault and can air past their license date The National Communications Commission (NCC) yesterday said that the Public Television Service (PTS) and 36 other television and radio broadcasters could continue airing, despite the commission’s inability to meet a quorum to review their license renewal applications. The licenses of PTS and the other channels are set to expire between this month and June. The National Communications Commission Organization Act (國家通訊傳播委員會組織法) stipulates that the commission must meet the mandated quorum of four to hold a valid meeting. The seven-member commission currently has only three commissioners. “We have informed the channel operators of the progress we have made in reviewing their license renewal applications, and
RSS